EA201490812A1 - Раствор для перорального введения - Google Patents

Раствор для перорального введения

Info

Publication number
EA201490812A1
EA201490812A1 EA201490812A EA201490812A EA201490812A1 EA 201490812 A1 EA201490812 A1 EA 201490812A1 EA 201490812 A EA201490812 A EA 201490812A EA 201490812 A EA201490812 A EA 201490812A EA 201490812 A1 EA201490812 A1 EA 201490812A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
solution
oral administration
compound
salt
Prior art date
Application number
EA201490812A
Other languages
English (en)
Inventor
Аяко Окамото
Original Assignee
Оцука Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оцука Фармасьютикал Ко., Лтд. filed Critical Оцука Фармасьютикал Ко., Лтд.
Publication of EA201490812A1 publication Critical patent/EA201490812A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предложен раствор 7-[4-(4-бензо[b]тиофен-4-ил-пиперазин-1-ил)бутокси]-1Н-хинолин-2-она (соединение (I)) или его соли, подходящий для перорального введения. Раствор для перорального введения, содержащий соединение (I) или его соль и по меньшей мере одно соединение, выбранное из группы, состоящей из молочной кислоты, фосфорной кислоты, гликолевой кислоты, яблочной кислоты, винной кислоты, лимонной кислоты, янтарной кислоты и уксусной кислоты, и имеющий значение рН в диапазоне 2,5-4,5.
EA201490812A 2011-10-19 2012-10-19 Раствор для перорального введения EA201490812A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19
PCT/JP2012/077668 WO2013058411A1 (en) 2011-10-19 2012-10-19 Solution for oral administration

Publications (1)

Publication Number Publication Date
EA201490812A1 true EA201490812A1 (ru) 2014-09-30

Family

ID=47178263

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201490812A EA201490812A1 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения
EA202190445A EA202190445A2 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190445A EA202190445A2 (ru) 2011-10-19 2012-10-19 Раствор для перорального введения

Country Status (35)

Country Link
US (7) US20140303183A1 (ru)
EP (1) EP2768508B1 (ru)
JP (1) JP6077534B2 (ru)
KR (1) KR101856283B1 (ru)
CN (2) CN103889426A (ru)
AR (1) AR088372A1 (ru)
AU (2) AU2012326978B2 (ru)
BR (1) BR112014009330A2 (ru)
CA (1) CA2851999C (ru)
CL (1) CL2014000967A1 (ru)
CO (1) CO6950486A2 (ru)
CY (1) CY1117794T1 (ru)
DK (1) DK2768508T3 (ru)
EA (2) EA201490812A1 (ru)
ES (1) ES2583137T3 (ru)
HK (1) HK1196773A1 (ru)
HR (1) HRP20160989T1 (ru)
HU (1) HUE028869T2 (ru)
IL (1) IL231988A (ru)
IN (1) IN2014DN02987A (ru)
JO (1) JO3190B1 (ru)
LT (1) LT2768508T (ru)
ME (1) ME02459B (ru)
MX (1) MX347309B (ru)
MY (1) MY169096A (ru)
PL (1) PL2768508T3 (ru)
PT (1) PT2768508T (ru)
RS (1) RS54967B1 (ru)
SG (1) SG11201401273SA (ru)
SI (1) SI2768508T1 (ru)
SM (1) SMT201600341B (ru)
TW (2) TWI632921B (ru)
UA (1) UA111506C2 (ru)
WO (1) WO2013058411A1 (ru)
ZA (1) ZA201402669B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
UA124498C2 (ru) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения (варианты)
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
US11013702B2 (en) * 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
JPWO2021029020A1 (ru) * 2019-08-13 2021-02-18
US20210401879A1 (en) * 2020-06-30 2021-12-30 Vireo Systems, Inc. Compositions for controlling odor and itch and methods of and devices for administering same
TWI820673B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑口溶膜組合物、其製備方法及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AU2003223093B2 (en) * 2002-05-03 2010-02-04 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
US20080032384A1 (en) * 2004-04-22 2008-02-07 Takehiko Nomura Pharmaceutical Preparation Containing Bacterial Cell Wall Skeleton
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
EP1891956B1 (en) * 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
ES2368758T3 (es) * 2005-09-01 2011-11-22 Baxter International Inc. (A Delaware Corporation) Formulación de argatroban que incluye un ácido como solubilizante.
JP2009545515A (ja) * 2006-07-31 2009-12-24 アスビオファーマ株式会社 液状製剤
EP2200584A2 (en) * 2007-09-17 2010-06-30 Schering Corporation Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
JP2010540448A (ja) * 2007-09-21 2010-12-24 フォレスト・ラボラトリーズ・ホールディングス・リミテッド 非経口投与に適したセフェム誘導体を含む可溶製剤
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
AR082494A1 (es) * 2010-08-24 2012-12-12 Otsuka Pharma Co Ltd Composicion en torta y en suspension con contenido de derivado de carbostirilo y derivado de aceite de silicona y/o aceite de silicona
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
AR085840A1 (es) * 2011-04-05 2013-10-30 Otsuka Pharma Co Ltd Medicamento que contiene un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1h-quinolin-2-ona

Also Published As

Publication number Publication date
CA2851999C (en) 2020-01-07
RS54967B1 (sr) 2016-11-30
ES2583137T3 (es) 2016-09-19
PL2768508T3 (pl) 2016-12-30
KR101856283B1 (ko) 2018-05-09
UA111506C2 (ru) 2016-05-10
CN103889426A (zh) 2014-06-25
SMT201600341B (it) 2016-11-10
US20180271858A1 (en) 2018-09-27
CN107823131A (zh) 2018-03-23
CA2851999A1 (en) 2013-04-25
CL2014000967A1 (es) 2014-10-03
MY169096A (en) 2019-02-18
EA202190445A2 (ru) 2021-08-31
IN2014DN02987A (ru) 2015-05-08
SI2768508T1 (sl) 2016-09-30
JP2014530801A (ja) 2014-11-20
HRP20160989T1 (hr) 2016-10-07
CY1117794T1 (el) 2017-05-17
US20140303183A1 (en) 2014-10-09
CO6950486A2 (es) 2014-05-20
DK2768508T3 (en) 2016-08-29
TWI632921B (zh) 2018-08-21
TW201737916A (zh) 2017-11-01
MX2014004529A (es) 2014-08-01
IL231988A0 (en) 2014-05-28
JP6077534B2 (ja) 2017-02-08
WO2013058411A1 (en) 2013-04-25
AR088372A1 (es) 2014-05-28
US20160213665A1 (en) 2016-07-28
SG11201401273SA (en) 2014-05-29
TW201330873A (zh) 2013-08-01
ME02459B (me) 2017-02-20
JO3190B1 (ar) 2018-03-08
PT2768508T (pt) 2016-08-17
HK1196773A1 (zh) 2014-12-24
KR20140083032A (ko) 2014-07-03
AU2017213570A1 (en) 2017-08-31
IL231988A (en) 2017-09-28
LT2768508T (lt) 2016-09-12
HUE028869T2 (en) 2017-01-30
NZ623523A (en) 2015-12-24
BR112014009330A2 (pt) 2017-04-11
MX347309B (es) 2017-04-21
US20170182036A1 (en) 2017-06-29
ZA201402669B (en) 2015-09-30
US20200171023A1 (en) 2020-06-04
AU2012326978A1 (en) 2014-05-22
TWI679977B (zh) 2019-12-21
EP2768508B1 (en) 2016-07-06
EP2768508A1 (en) 2014-08-27
US20210236483A1 (en) 2021-08-05
AU2012326978B2 (en) 2017-08-31
US20240009186A1 (en) 2024-01-11

Similar Documents

Publication Publication Date Title
EA201490812A1 (ru) Раствор для перорального введения
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
MX2016004992A (es) Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il ) amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteínas cinasa dependientes de adn (adn-pk).
MX355228B (es) Composicion fungicida agricola y horticola.
MX2014002113A (es) Iminotiazinas sustituidas en 2-espiro y sus mono y bioxidos como inhibidores de enzima de disociacion de proteina precursora amiloide del sitio beta, composiciones, y su uso.
EA201001699A1 (ru) Сложные эфиры и тиоэфиры тиазол-4-карбоновой кислоты в качестве средств защиты растений
AU2012243329A8 (en) 5-substituted iminothiazines and their mono-and dioxides as BACE inhibitors,compositions,and their use
UA110347C2 (ru) Производные 6-циклоалкил-1,5-дигидропиразоло [3,4-d] пиримидин-4-ону и их применение в качестве ингибиторов pde9a
MX346336B (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa.
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
EA201390347A1 (ru) Лечение заболеваний
JP2014530801A5 (ru)
CA2920410C (en) Thienopiperidine derivative and use thereof
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
EA201490175A1 (ru) Составы дезоксихолевой кислоты и ее солей
EA201391026A1 (ru) Кристаллическое производное оксазина и его применение в качестве ингибитора bace
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
SMT201300112B (it) Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene
ATE505193T1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts